Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(16)30387-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report.
Transl Lung Cancer Res
December 2024
Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Background: Small-cell lung cancer (SCLC) is highly malignant. Despite being highly sensitive to initial chemotherapy and radiotherapy, the recurrence rate is high. Atezolizumab is the first immune checkpoint inhibitor (ICI) that has been proven to provide an overall survival (OS) benefit for extensive-stage SCLC (ES-SCLC), making ICIs in combination with chemotherapy the standard first-line treatment for ES-SCLC.
View Article and Find Full Text PDFReal-world evidence in extensive disease small cell lung cancer: The missing piece of the puzzle.
Crit Rev Oncol Hematol
January 2025
Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona, Italy. Electronic address:
Small cell lung cancer (SCLC) is a highly aggressive disease, often diagnosed at an advanced stage and with limited treatment options. In recent years, immunotherapy has been approved in combination with chemotherapy in the first line setting of extensive stage disease (ES-SCLC). However, only 10-15% of patients with ES-SCLC treated with chemoimmunotherapy (CT-IO) experience a long-term benefit.
View Article and Find Full Text PDFOutcomes of endometrial cancer prevention strategies in patients with Lynch syndrome: a nationwide cohort study in the Netherlands.
EClinicalMedicine
January 2025
Department of Clinical Genetics, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Background: Female Lynch syndrome carriers have an increased risk of developing endometrial cancer. Regardless, research on endometrial carcinoma tumorigenesis is scarce and no uniform, evidence-based gynaecological management guidelines exist. We therefore described gynaecological surveillance and surgery outcomes in a nation-wide Lynch syndrome cohort.
View Article and Find Full Text PDFSafety and efficacy of mecapegfilgrastim in preventing neutropenia in patients with head and neck cancer: a multicenter, prospective, observational, real-world study.
Transl Cancer Res
December 2024
GI Cancer Center, Nanjing Tianyinshan Hospital, Nanjing, China.
Background: Mecapegfilgrastim, a long-acting granulocyte colony-stimulating factor, is approved in China for neutropenia prevention. However, data on its safety and efficacy in patients with head and neck cancer remain limited. This study aimed to evaluate the safety and efficacy of mecapegfilgrastim in preventing neutropenia among these patients undergoing chemotherapy, particularly those receiving chemoradiotherapy or chemoimmunotherapy.
View Article and Find Full Text PDFXenogeneic platelet-rich plasma lotion for preventing acute radiation dermatitis in patients with breast cancer undergoing radiotherapy: An open-label, randomized controlled trial.
JPRAS Open
March 2025
Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Background: Breast cancer patients experience acute radiation dermatitis (ARD) during radiation therapy (RT). This study investigated the prophylactic effect of a newly developed xenogeneic platelet-rich plasma (PRP) lotion on ARD for breast cancer patients.
Methods: This study enrolled patients with ductal carcinoma in situ and early-stage invasive breast cancers after breast-conserving surgery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!